Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.

von zur Mühlen, B; Kahan, T; Hägg, A; Millgård, J; Lind, L

von zur Mühlen, B; Kahan, T; Hägg, A; Millgård, J; Lind, L.

Affiliation

von zur Mühlen B; Department of Internal Medicine, University Hospital, Uppsala, Sweden. bengt.muhlen@medsci.uu.se

J Hypertens ; 19(10): 1813-8, 2001 Oct.

Article in En | MEDLINE | ID: mdl-11593101

Subject(s)

Adrenergic beta-Antagonists/therapeutic use; Antihypertensive Agents/therapeutic use; Atenolol/therapeutic use; Biphenyl Compounds/therapeutic use; Endothelium, Vascular/drug effects; Endothelium, Vascular/physiopathology; Hypertension/drug therapy; Hypertension/physiopathology; Tetrazoles/therapeutic use; Angiotensin Receptor Antagonists; Double-Blind Method; Female; Forearm/blood supply; Humans; Irbesartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Regional Blood Flow/drug effects; Vasodilation/drug effects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Atenolol / Tetrazoles / Biphenyl Compounds / Endothelium, Vascular / Adrenergic beta-Antagonists / Hypertension / Antihypertensive Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: J Hypertens Year: 2001 Document type: Article Affiliation country: Sweden Country of publication: Netherlands

Search on Google

Add to My VHL

XML

PubMed Links